Your browser is no longer supported. Please, upgrade your browser.
Five Prime Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.68 Insider Own0.80% Shs Outstand46.32M Perf Week-19.43%
Market Cap594.54M Forward P/E- EPS next Y-2.08 Insider Trans-95.23% Shs Float36.10M Perf Month-26.85%
Income-94.80M PEG- EPS next Q-0.53 Inst Own47.30% Short Float3.17% Perf Quarter143.91%
Sales17.10M P/S34.77 EPS this Y5.10% Inst Trans-23.80% Short Ratio0.45 Perf Half Y101.27%
Book/sh2.68 P/B5.31 EPS next Y9.60% ROA-49.10% Target Price27.14 Perf Year176.12%
Cash/sh2.66 P/C5.34 EPS next 5Y- ROE-75.80% 52W Range1.75 - 24.70 Perf YTD-16.40%
Dividend- P/FCF- EPS past 5Y-16.90% ROI-94.30% 52W High-42.43% Beta4.45
Dividend %- Quick Ratio5.30 Sales past 5Y-5.00% Gross Margin- 52W Low712.57% ATR1.50
Employees87 Current Ratio5.30 Sales Q/Q-33.30% Oper. Margin- RSI (14)37.71 Volatility11.42% 8.20%
OptionableYes Debt/Eq0.00 EPS Q/Q27.80% Profit Margin- Rel Volume0.70 Prev Close15.96
ShortableYes LT Debt/Eq0.00 EarningsNov 03 AMC Payout- Avg Volume2.53M Price14.22
Recom1.60 SMA20-20.68% SMA50-14.16% SMA20085.11% Volume1,759,927 Change-10.90%
Nov-11-20Upgrade Wells Fargo Equal Weight → Overweight $34
Nov-11-20Upgrade ROTH Capital Neutral → Buy $9 → $30
Nov-11-20Upgrade JP Morgan Underweight → Neutral $14
Sep-22-20Upgrade Guggenheim Neutral → Buy $11
Jun-22-20Upgrade Wedbush Neutral → Outperform $5 → $9
Feb-28-20Downgrade JP Morgan Neutral → Underweight
Feb-18-20Downgrade Wedbush Outperform → Neutral
Nov-20-19Resumed Guggenheim Neutral
Oct-01-19Downgrade Guggenheim Buy → Neutral
Jun-03-19Downgrade Wells Fargo Outperform → Market Perform
May-29-19Initiated ROTH Capital Neutral $10
Apr-12-19Resumed Guggenheim Buy $24
Sep-13-18Resumed Leerink Partners Outperform $24
Jun-28-18Initiated Raymond James Mkt Perform
Jun-15-18Initiated JP Morgan Neutral $19
May-18-18Initiated Wedbush Neutral
Nov-06-17Reiterated RBC Capital Mkts Outperform $41 → $50
Sep-15-17Initiated RBC Capital Mkts Outperform $41
Mar-02-17Initiated Instinet Buy $94
Oct-25-16Initiated Citigroup Buy
Jan-15-21 06:55AM  
Dec-21-20 01:20AM  
Dec-17-20 11:18PM  
Dec-09-20 05:00PM  
Dec-08-20 10:00AM  
Dec-07-20 08:29AM  
Dec-05-20 04:00PM  
Nov-17-20 05:00PM  
Nov-13-20 07:40AM  
Nov-12-20 10:00PM  
Nov-11-20 05:45PM  
Nov-10-20 07:00PM  
Nov-06-20 06:47AM  
Nov-03-20 05:15PM  
Nov-02-20 06:30PM  
Oct-28-20 12:32PM  
Oct-27-20 10:29PM  
Oct-13-20 02:47PM  
Oct-12-20 08:48AM  
Oct-09-20 09:50AM  
Sep-22-20 09:36AM  
Sep-09-20 06:30PM  
Aug-13-20 03:30PM  
Aug-10-20 12:56PM  
Aug-06-20 08:30PM  
Jul-30-20 12:33PM  
Jul-29-20 07:00PM  
Jun-26-20 09:17AM  
Jun-22-20 10:48AM  
Jun-11-20 07:53AM  
May-15-20 09:37AM  
May-10-20 09:55AM  
May-07-20 04:05PM  
Apr-30-20 04:05PM  
Apr-22-20 04:05PM  
Apr-14-20 09:00AM  
Apr-09-20 07:35AM  
Mar-20-20 03:32AM  
Mar-13-20 09:25AM  
Feb-27-20 05:45PM  
Feb-25-20 04:22PM  
Feb-20-20 12:31PM  
Feb-19-20 09:25AM  
Feb-18-20 09:25AM  
Feb-13-20 04:05PM  
Jan-10-20 09:28AM  
Dec-30-19 01:05PM  
Dec-27-19 02:26PM  
Dec-26-19 04:05PM  
Dec-20-19 01:54PM  
Dec-16-19 06:17PM  
Dec-10-19 11:14AM  
Nov-09-19 07:00AM  
Nov-08-19 01:02PM  
Nov-06-19 06:45PM  
Oct-30-19 10:33AM  
Oct-24-19 04:01PM  
Oct-11-19 04:04PM  
Oct-10-19 09:57PM  
Oct-02-19 07:30AM  
Sep-30-19 03:01AM  
Sep-20-19 09:59AM  
Sep-19-19 04:05PM  
Aug-22-19 07:45PM  
Aug-15-19 10:16PM  
Aug-07-19 06:25PM  
Aug-01-19 03:06PM  
Jun-25-19 11:56AM  
Jun-24-19 04:05PM  
Jun-18-19 08:50AM  
Jun-09-19 03:05PM  
Jun-01-19 09:01AM  
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sarena Francis WillardChief Strategy OfficerDec 11Option Exercise0.0022,0000138,010Dec 15 12:19 PM
Smith David VExecutive Vice President & CFODec 11Option Exercise0.0022,000089,561Dec 15 12:09 PM
Collins Helen LouiseEVP and Chief Medical OfficerDec 11Option Exercise0.0022,000097,117Dec 15 12:00 PM
RINGO WILLIAM RDirectorNov 11Option Exercise2.4178,959190,36962,959Nov 13 12:17 PM
Sarena Francis WillardChief Strategy OfficerNov 11Option Exercise0.0022,0000127,011Nov 13 12:38 PM
Smith David VExecutive Vice President & CFONov 11Option Exercise0.0022,000085,389Nov 13 12:29 PM
Collins Helen LouiseEVP and Chief Medical OfficerNov 11Option Exercise0.0022,000086,156Nov 13 12:25 PM
BVF PARTNERS L P/ILSee Explanaton of ResponsesNov 11Sale20.197,393,340149,247,13781,263Nov 13 05:29 PM
RINGO WILLIAM RDirectorNov 11Sale22.5078,9591,776,57810,000Nov 13 12:17 PM
BVF PARTNERS L P/IL10% OwnerNov 06Buy4.9830,000149,5204,611,909Nov 06 06:30 PM
BVF PARTNERS L P/IL10% OwnerNov 04Buy4.88416,5622,034,5724,594,679Nov 06 06:30 PM
BVF PARTNERS L P/IL10% OwnerOct 06Buy5.04345,2411,738,2884,336,875Oct 08 05:27 PM
BVF PARTNERS L P/IL10% OwnerSep 22Buy3.8032122541,116Sep 24 07:49 PM
BVF PARTNERS L P/IL10% OwnerMay 14Buy4.10293,5871,203,7074,179,093May 18 08:02 PM